Global (United States, European Union and China) Cardiac Biomarker

Cardiac Biomarker Comprehensive Study by Type (Myocardial Muscle Creatine Kinase, Troponins, Myoglobin, Brain Natriuretic Peptide, Ischemia-modified Albumin, Others), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Others), End Users (Hospitals and Clinics, Ambulatory Clinical Services, Others), Testing Location Type (Point of Care Testing, Laboratory Testing) Players and Region - Global Market Outlook to 2024

Cardiac Biomarker Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Cardiac Biomarker Market Overview:
cardiac biomarker is also known as cardiac markers, are released into the bloodstream when the heart is stressed, or its muscles are damaged. These markers include different types of enzymes, hormones, and proteins, such as cardiac troponins, creatine kinase (CK), ischemia-modified albumin (IMA), and myoglobin. As cardiac marker testing offers higher accuracy and can identify the conditions in the early stages of presentation, they are gaining traction across the globe.

Market Drivers
  • Increasing Number of Patients Suffering from ACS
  • Growing Prevalence of Cardiovascular Diseases

Market Trend
  • Technological Advancements using Cardio Biomarkers Combinations and Increasing Point of Care (POC) Testing


Opportunities
  • Increase in the Use of Personalized Medicine
  • Rise in Point of Care Testing Using Cardiac Biomarkers

Challenges
  • Complex Process Related to the Course and Several Stringent Government Regulations


Competitive Landscape:

Some of the key players profiled in the report are Alere Inc. (A Abbott Lab Company) (United States), Roche Holding AG (Switzerland), BG Medicine (Cambodia), Biomerieux (France), Critical Diagnostics (United States), DiaDexus (United States), Response Biomedical (Canada), Siemens Healthcare (Germany), Singulex Inc. (united States) and Thermo Fisher Scientific (United States). Considering Market by End Users, the sub-segment i.e. Hospitals and Clinics will boost the Cardiac Biomarker market. Considering Market by Testing Location Type, the sub-segment i.e. Point of Care Testing will boost the Cardiac Biomarker market.

Market Highlights:

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Cardiac Biomarker market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Cardiac Biomarker market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Cardiac Biomarker Manufacturers, Technology Providers, Raw Material Suppliers, Cardiac Biomarker Distributors, End Users and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Myocardial Muscle Creatine Kinase
  • Troponins
  • Myoglobin
  • Brain Natriuretic Peptide
  • Ischemia-modified Albumin
  • Others
By Application
  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Others
By End Users
  • Hospitals and Clinics
  • Ambulatory Clinical Services
  • Others

By Testing Location Type
  • Point of Care Testing
  • Laboratory Testing

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Patients Suffering from ACS
      • 3.2.2. Growing Prevalence of Cardiovascular Diseases
    • 3.3. Market Challenges
      • 3.3.1. Complex Process Related to the Course and Several Stringent Government Regulations
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements using Cardio Biomarkers Combinations and Increasing Point of Care (POC) Testing
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cardiac Biomarker, by Type, Application, End Users, Testing Location Type and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Cardiac Biomarker (Value)
      • 5.2.1. Global Cardiac Biomarker by: Type (Value)
        • 5.2.1.1. Myocardial Muscle Creatine Kinase
        • 5.2.1.2. Troponins
        • 5.2.1.3. Myoglobin
        • 5.2.1.4. Brain Natriuretic Peptide
        • 5.2.1.5. Ischemia-modified Albumin
        • 5.2.1.6. Others
      • 5.2.2. Global Cardiac Biomarker by: Application (Value)
        • 5.2.2.1. Myocardial Infarction
        • 5.2.2.2. Congestive Heart Failure
        • 5.2.2.3. Acute Coronary Syndrome
        • 5.2.2.4. Atherosclerosis
        • 5.2.2.5. Others
      • 5.2.3. Global Cardiac Biomarker by: End Users (Value)
        • 5.2.3.1. Hospitals and Clinics
        • 5.2.3.2. Ambulatory Clinical Services
        • 5.2.3.3. Others
      • 5.2.4. Global Cardiac Biomarker by: Testing Location Type (Value)
        • 5.2.4.1. Point of Care Testing
        • 5.2.4.2. Laboratory Testing
      • 5.2.5. Global Cardiac Biomarker Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Cardiac Biomarker (Volume)
      • 5.3.1. Global Cardiac Biomarker by: Type (Volume)
        • 5.3.1.1. Myocardial Muscle Creatine Kinase
        • 5.3.1.2. Troponins
        • 5.3.1.3. Myoglobin
        • 5.3.1.4. Brain Natriuretic Peptide
        • 5.3.1.5. Ischemia-modified Albumin
        • 5.3.1.6. Others
      • 5.3.2. Global Cardiac Biomarker by: Application (Volume)
        • 5.3.2.1. Myocardial Infarction
        • 5.3.2.2. Congestive Heart Failure
        • 5.3.2.3. Acute Coronary Syndrome
        • 5.3.2.4. Atherosclerosis
        • 5.3.2.5. Others
      • 5.3.3. Global Cardiac Biomarker by: End Users (Volume)
        • 5.3.3.1. Hospitals and Clinics
        • 5.3.3.2. Ambulatory Clinical Services
        • 5.3.3.3. Others
      • 5.3.4. Global Cardiac Biomarker by: Testing Location Type (Volume)
        • 5.3.4.1. Point of Care Testing
        • 5.3.4.2. Laboratory Testing
      • 5.3.5. Global Cardiac Biomarker Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Cardiac Biomarker (Price)
      • 5.4.1. Global Cardiac Biomarker by: Type (Price)
  • 6. Cardiac Biomarker: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Alere Inc. (A Abbott Lab Company) (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Roche Holding AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BG Medicine (Cambodia)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Biomerieux (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Critical Diagnostics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. DiaDexus (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Response Biomedical (Canada)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Siemens Healthcare (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Singulex Inc. (united States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Thermo Fisher Scientific (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cardiac Biomarker Sale, by Type, Application, End Users, Testing Location Type and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Cardiac Biomarker (Value)
      • 7.2.1. Global Cardiac Biomarker by: Type (Value)
        • 7.2.1.1. Myocardial Muscle Creatine Kinase
        • 7.2.1.2. Troponins
        • 7.2.1.3. Myoglobin
        • 7.2.1.4. Brain Natriuretic Peptide
        • 7.2.1.5. Ischemia-modified Albumin
        • 7.2.1.6. Others
      • 7.2.2. Global Cardiac Biomarker by: Application (Value)
        • 7.2.2.1. Myocardial Infarction
        • 7.2.2.2. Congestive Heart Failure
        • 7.2.2.3. Acute Coronary Syndrome
        • 7.2.2.4. Atherosclerosis
        • 7.2.2.5. Others
      • 7.2.3. Global Cardiac Biomarker by: End Users (Value)
        • 7.2.3.1. Hospitals and Clinics
        • 7.2.3.2. Ambulatory Clinical Services
        • 7.2.3.3. Others
      • 7.2.4. Global Cardiac Biomarker by: Testing Location Type (Value)
        • 7.2.4.1. Point of Care Testing
        • 7.2.4.2. Laboratory Testing
      • 7.2.5. Global Cardiac Biomarker Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Cardiac Biomarker (Volume)
      • 7.3.1. Global Cardiac Biomarker by: Type (Volume)
        • 7.3.1.1. Myocardial Muscle Creatine Kinase
        • 7.3.1.2. Troponins
        • 7.3.1.3. Myoglobin
        • 7.3.1.4. Brain Natriuretic Peptide
        • 7.3.1.5. Ischemia-modified Albumin
        • 7.3.1.6. Others
      • 7.3.2. Global Cardiac Biomarker by: Application (Volume)
        • 7.3.2.1. Myocardial Infarction
        • 7.3.2.2. Congestive Heart Failure
        • 7.3.2.3. Acute Coronary Syndrome
        • 7.3.2.4. Atherosclerosis
        • 7.3.2.5. Others
      • 7.3.3. Global Cardiac Biomarker by: End Users (Volume)
        • 7.3.3.1. Hospitals and Clinics
        • 7.3.3.2. Ambulatory Clinical Services
        • 7.3.3.3. Others
      • 7.3.4. Global Cardiac Biomarker by: Testing Location Type (Volume)
        • 7.3.4.1. Point of Care Testing
        • 7.3.4.2. Laboratory Testing
      • 7.3.5. Global Cardiac Biomarker Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Cardiac Biomarker (Price)
      • 7.4.1. Global Cardiac Biomarker by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cardiac Biomarker: by Type(USD Million)
  • Table 2. Cardiac Biomarker Myocardial Muscle Creatine Kinase , by Region USD Million (2013-2018)
  • Table 3. Cardiac Biomarker Troponins , by Region USD Million (2013-2018)
  • Table 4. Cardiac Biomarker Myoglobin , by Region USD Million (2013-2018)
  • Table 5. Cardiac Biomarker Brain Natriuretic Peptide , by Region USD Million (2013-2018)
  • Table 6. Cardiac Biomarker Ischemia-modified Albumin , by Region USD Million (2013-2018)
  • Table 7. Cardiac Biomarker Others , by Region USD Million (2013-2018)
  • Table 8. Cardiac Biomarker: by Application(USD Million)
  • Table 9. Cardiac Biomarker Myocardial Infarction , by Region USD Million (2013-2018)
  • Table 10. Cardiac Biomarker Congestive Heart Failure , by Region USD Million (2013-2018)
  • Table 11. Cardiac Biomarker Acute Coronary Syndrome , by Region USD Million (2013-2018)
  • Table 12. Cardiac Biomarker Atherosclerosis , by Region USD Million (2013-2018)
  • Table 13. Cardiac Biomarker Others , by Region USD Million (2013-2018)
  • Table 14. Cardiac Biomarker: by End Users(USD Million)
  • Table 15. Cardiac Biomarker Hospitals and Clinics , by Region USD Million (2013-2018)
  • Table 16. Cardiac Biomarker Ambulatory Clinical Services , by Region USD Million (2013-2018)
  • Table 17. Cardiac Biomarker Others , by Region USD Million (2013-2018)
  • Table 18. Cardiac Biomarker: by Testing Location Type(USD Million)
  • Table 19. Cardiac Biomarker Point of Care Testing , by Region USD Million (2013-2018)
  • Table 20. Cardiac Biomarker Laboratory Testing , by Region USD Million (2013-2018)
  • Table 21. South America Cardiac Biomarker, by Country USD Million (2013-2018)
  • Table 22. South America Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 23. South America Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 24. South America Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 25. South America Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 26. Brazil Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 27. Brazil Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 28. Brazil Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 29. Brazil Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 30. Argentina Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 31. Argentina Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 32. Argentina Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 33. Argentina Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 34. Rest of South America Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 35. Rest of South America Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 36. Rest of South America Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 37. Rest of South America Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 38. Asia Pacific Cardiac Biomarker, by Country USD Million (2013-2018)
  • Table 39. Asia Pacific Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 40. Asia Pacific Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 41. Asia Pacific Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 42. Asia Pacific Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 43. China Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 44. China Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 45. China Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 46. China Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 47. Japan Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 48. Japan Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 49. Japan Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 50. Japan Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 51. India Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 52. India Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 53. India Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 54. India Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 55. South Korea Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 56. South Korea Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 57. South Korea Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 58. South Korea Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 59. Taiwan Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 60. Taiwan Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 61. Taiwan Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 62. Taiwan Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 63. Australia Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 64. Australia Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 65. Australia Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 66. Australia Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 67. Rest of Asia-Pacific Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 68. Rest of Asia-Pacific Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 69. Rest of Asia-Pacific Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 70. Rest of Asia-Pacific Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 71. Europe Cardiac Biomarker, by Country USD Million (2013-2018)
  • Table 72. Europe Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 73. Europe Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 74. Europe Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 75. Europe Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 76. Germany Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 77. Germany Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 78. Germany Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 79. Germany Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 80. France Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 81. France Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 82. France Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 83. France Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 84. Italy Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 85. Italy Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 86. Italy Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 87. Italy Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 88. United Kingdom Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 89. United Kingdom Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 90. United Kingdom Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 91. United Kingdom Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 92. Netherlands Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 93. Netherlands Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 94. Netherlands Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 95. Netherlands Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 96. Rest of Europe Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 97. Rest of Europe Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 98. Rest of Europe Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 99. Rest of Europe Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 100. MEA Cardiac Biomarker, by Country USD Million (2013-2018)
  • Table 101. MEA Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 102. MEA Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 103. MEA Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 104. MEA Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 105. Middle East Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 106. Middle East Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 107. Middle East Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 108. Middle East Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 109. Africa Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 110. Africa Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 111. Africa Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 112. Africa Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 113. North America Cardiac Biomarker, by Country USD Million (2013-2018)
  • Table 114. North America Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 115. North America Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 116. North America Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 117. North America Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 118. United States Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 119. United States Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 120. United States Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 121. United States Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 122. Canada Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 123. Canada Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 124. Canada Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 125. Canada Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 126. Mexico Cardiac Biomarker, by Type USD Million (2013-2018)
  • Table 127. Mexico Cardiac Biomarker, by Application USD Million (2013-2018)
  • Table 128. Mexico Cardiac Biomarker, by End Users USD Million (2013-2018)
  • Table 129. Mexico Cardiac Biomarker, by Testing Location Type USD Million (2013-2018)
  • Table 130. Cardiac Biomarker Sales: by Type(K Unit)
  • Table 131. Cardiac Biomarker Sales Myocardial Muscle Creatine Kinase , by Region K Unit (2013-2018)
  • Table 132. Cardiac Biomarker Sales Troponins , by Region K Unit (2013-2018)
  • Table 133. Cardiac Biomarker Sales Myoglobin , by Region K Unit (2013-2018)
  • Table 134. Cardiac Biomarker Sales Brain Natriuretic Peptide , by Region K Unit (2013-2018)
  • Table 135. Cardiac Biomarker Sales Ischemia-modified Albumin , by Region K Unit (2013-2018)
  • Table 136. Cardiac Biomarker Sales Others , by Region K Unit (2013-2018)
  • Table 137. Cardiac Biomarker Sales: by Application(K Unit)
  • Table 138. Cardiac Biomarker Sales Myocardial Infarction , by Region K Unit (2013-2018)
  • Table 139. Cardiac Biomarker Sales Congestive Heart Failure , by Region K Unit (2013-2018)
  • Table 140. Cardiac Biomarker Sales Acute Coronary Syndrome , by Region K Unit (2013-2018)
  • Table 141. Cardiac Biomarker Sales Atherosclerosis , by Region K Unit (2013-2018)
  • Table 142. Cardiac Biomarker Sales Others , by Region K Unit (2013-2018)
  • Table 143. Cardiac Biomarker Sales: by End Users(K Unit)
  • Table 144. Cardiac Biomarker Sales Hospitals and Clinics , by Region K Unit (2013-2018)
  • Table 145. Cardiac Biomarker Sales Ambulatory Clinical Services , by Region K Unit (2013-2018)
  • Table 146. Cardiac Biomarker Sales Others , by Region K Unit (2013-2018)
  • Table 147. Cardiac Biomarker Sales: by Testing Location Type(K Unit)
  • Table 148. Cardiac Biomarker Sales Point of Care Testing , by Region K Unit (2013-2018)
  • Table 149. Cardiac Biomarker Sales Laboratory Testing , by Region K Unit (2013-2018)
  • Table 150. South America Cardiac Biomarker Sales, by Country K Unit (2013-2018)
  • Table 151. South America Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 152. South America Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 153. South America Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 154. South America Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 155. Brazil Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 156. Brazil Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 157. Brazil Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 158. Brazil Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 159. Argentina Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 160. Argentina Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 161. Argentina Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 162. Argentina Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 163. Rest of South America Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 164. Rest of South America Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 165. Rest of South America Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 166. Rest of South America Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 167. Asia Pacific Cardiac Biomarker Sales, by Country K Unit (2013-2018)
  • Table 168. Asia Pacific Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 169. Asia Pacific Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 170. Asia Pacific Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 171. Asia Pacific Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 172. China Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 173. China Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 174. China Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 175. China Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 176. Japan Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 177. Japan Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 178. Japan Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 179. Japan Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 180. India Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 181. India Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 182. India Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 183. India Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 184. South Korea Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 185. South Korea Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 186. South Korea Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 187. South Korea Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 188. Taiwan Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 189. Taiwan Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 190. Taiwan Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 191. Taiwan Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 192. Australia Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 193. Australia Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 194. Australia Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 195. Australia Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 196. Rest of Asia-Pacific Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 197. Rest of Asia-Pacific Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 198. Rest of Asia-Pacific Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 199. Rest of Asia-Pacific Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 200. Europe Cardiac Biomarker Sales, by Country K Unit (2013-2018)
  • Table 201. Europe Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 202. Europe Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 203. Europe Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 204. Europe Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 205. Germany Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 206. Germany Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 207. Germany Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 208. Germany Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 209. France Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 210. France Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 211. France Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 212. France Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 213. Italy Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 214. Italy Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 215. Italy Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 216. Italy Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 217. United Kingdom Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 218. United Kingdom Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 219. United Kingdom Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 220. United Kingdom Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 221. Netherlands Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 222. Netherlands Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 223. Netherlands Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 224. Netherlands Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 225. Rest of Europe Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 226. Rest of Europe Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 227. Rest of Europe Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 228. Rest of Europe Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 229. MEA Cardiac Biomarker Sales, by Country K Unit (2013-2018)
  • Table 230. MEA Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 231. MEA Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 232. MEA Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 233. MEA Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 234. Middle East Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 235. Middle East Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 236. Middle East Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 237. Middle East Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 238. Africa Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 239. Africa Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 240. Africa Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 241. Africa Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 242. North America Cardiac Biomarker Sales, by Country K Unit (2013-2018)
  • Table 243. North America Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 244. North America Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 245. North America Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 246. North America Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 247. United States Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 248. United States Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 249. United States Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 250. United States Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 251. Canada Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 252. Canada Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 253. Canada Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 254. Canada Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 255. Mexico Cardiac Biomarker Sales, by Type K Unit (2013-2018)
  • Table 256. Mexico Cardiac Biomarker Sales, by Application K Unit (2013-2018)
  • Table 257. Mexico Cardiac Biomarker Sales, by End Users K Unit (2013-2018)
  • Table 258. Mexico Cardiac Biomarker Sales, by Testing Location Type K Unit (2013-2018)
  • Table 259. Cardiac Biomarker: by Type(USD/Units)
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Cardiac Biomarker: by Type(USD Million)
  • Table 271. Cardiac Biomarker Myocardial Muscle Creatine Kinase , by Region USD Million (2019-2024)
  • Table 272. Cardiac Biomarker Troponins , by Region USD Million (2019-2024)
  • Table 273. Cardiac Biomarker Myoglobin , by Region USD Million (2019-2024)
  • Table 274. Cardiac Biomarker Brain Natriuretic Peptide , by Region USD Million (2019-2024)
  • Table 275. Cardiac Biomarker Ischemia-modified Albumin , by Region USD Million (2019-2024)
  • Table 276. Cardiac Biomarker Others , by Region USD Million (2019-2024)
  • Table 277. Cardiac Biomarker: by Application(USD Million)
  • Table 278. Cardiac Biomarker Myocardial Infarction , by Region USD Million (2019-2024)
  • Table 279. Cardiac Biomarker Congestive Heart Failure , by Region USD Million (2019-2024)
  • Table 280. Cardiac Biomarker Acute Coronary Syndrome , by Region USD Million (2019-2024)
  • Table 281. Cardiac Biomarker Atherosclerosis , by Region USD Million (2019-2024)
  • Table 282. Cardiac Biomarker Others , by Region USD Million (2019-2024)
  • Table 283. Cardiac Biomarker: by End Users(USD Million)
  • Table 284. Cardiac Biomarker Hospitals and Clinics , by Region USD Million (2019-2024)
  • Table 285. Cardiac Biomarker Ambulatory Clinical Services , by Region USD Million (2019-2024)
  • Table 286. Cardiac Biomarker Others , by Region USD Million (2019-2024)
  • Table 287. Cardiac Biomarker: by Testing Location Type(USD Million)
  • Table 288. Cardiac Biomarker Point of Care Testing , by Region USD Million (2019-2024)
  • Table 289. Cardiac Biomarker Laboratory Testing , by Region USD Million (2019-2024)
  • Table 290. South America Cardiac Biomarker, by Country USD Million (2019-2024)
  • Table 291. South America Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 292. South America Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 293. South America Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 294. South America Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 295. Brazil Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 296. Brazil Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 297. Brazil Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 298. Brazil Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 299. Argentina Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 300. Argentina Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 301. Argentina Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 302. Argentina Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 303. Rest of South America Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 304. Rest of South America Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 305. Rest of South America Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 306. Rest of South America Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 307. Asia Pacific Cardiac Biomarker, by Country USD Million (2019-2024)
  • Table 308. Asia Pacific Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 309. Asia Pacific Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 310. Asia Pacific Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 311. Asia Pacific Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 312. China Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 313. China Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 314. China Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 315. China Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 316. Japan Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 317. Japan Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 318. Japan Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 319. Japan Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 320. India Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 321. India Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 322. India Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 323. India Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 324. South Korea Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 325. South Korea Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 326. South Korea Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 327. South Korea Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 328. Taiwan Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 329. Taiwan Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 330. Taiwan Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 331. Taiwan Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 332. Australia Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 333. Australia Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 334. Australia Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 335. Australia Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 336. Rest of Asia-Pacific Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 337. Rest of Asia-Pacific Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 338. Rest of Asia-Pacific Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 339. Rest of Asia-Pacific Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 340. Europe Cardiac Biomarker, by Country USD Million (2019-2024)
  • Table 341. Europe Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 342. Europe Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 343. Europe Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 344. Europe Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 345. Germany Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 346. Germany Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 347. Germany Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 348. Germany Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 349. France Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 350. France Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 351. France Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 352. France Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 353. Italy Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 354. Italy Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 355. Italy Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 356. Italy Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 357. United Kingdom Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 358. United Kingdom Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 359. United Kingdom Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 360. United Kingdom Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 361. Netherlands Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 362. Netherlands Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 363. Netherlands Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 364. Netherlands Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 365. Rest of Europe Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 366. Rest of Europe Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 367. Rest of Europe Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 368. Rest of Europe Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 369. MEA Cardiac Biomarker, by Country USD Million (2019-2024)
  • Table 370. MEA Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 371. MEA Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 372. MEA Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 373. MEA Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 374. Middle East Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 375. Middle East Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 376. Middle East Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 377. Middle East Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 378. Africa Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 379. Africa Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 380. Africa Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 381. Africa Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 382. North America Cardiac Biomarker, by Country USD Million (2019-2024)
  • Table 383. North America Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 384. North America Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 385. North America Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 386. North America Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 387. United States Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 388. United States Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 389. United States Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 390. United States Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 391. Canada Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 392. Canada Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 393. Canada Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 394. Canada Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 395. Mexico Cardiac Biomarker, by Type USD Million (2019-2024)
  • Table 396. Mexico Cardiac Biomarker, by Application USD Million (2019-2024)
  • Table 397. Mexico Cardiac Biomarker, by End Users USD Million (2019-2024)
  • Table 398. Mexico Cardiac Biomarker, by Testing Location Type USD Million (2019-2024)
  • Table 399. Cardiac Biomarker Sales: by Type(K Unit)
  • Table 400. Cardiac Biomarker Sales Myocardial Muscle Creatine Kinase , by Region K Unit (2019-2024)
  • Table 401. Cardiac Biomarker Sales Troponins , by Region K Unit (2019-2024)
  • Table 402. Cardiac Biomarker Sales Myoglobin , by Region K Unit (2019-2024)
  • Table 403. Cardiac Biomarker Sales Brain Natriuretic Peptide , by Region K Unit (2019-2024)
  • Table 404. Cardiac Biomarker Sales Ischemia-modified Albumin , by Region K Unit (2019-2024)
  • Table 405. Cardiac Biomarker Sales Others , by Region K Unit (2019-2024)
  • Table 406. Cardiac Biomarker Sales: by Application(K Unit)
  • Table 407. Cardiac Biomarker Sales Myocardial Infarction , by Region K Unit (2019-2024)
  • Table 408. Cardiac Biomarker Sales Congestive Heart Failure , by Region K Unit (2019-2024)
  • Table 409. Cardiac Biomarker Sales Acute Coronary Syndrome , by Region K Unit (2019-2024)
  • Table 410. Cardiac Biomarker Sales Atherosclerosis , by Region K Unit (2019-2024)
  • Table 411. Cardiac Biomarker Sales Others , by Region K Unit (2019-2024)
  • Table 412. Cardiac Biomarker Sales: by End Users(K Unit)
  • Table 413. Cardiac Biomarker Sales Hospitals and Clinics , by Region K Unit (2019-2024)
  • Table 414. Cardiac Biomarker Sales Ambulatory Clinical Services , by Region K Unit (2019-2024)
  • Table 415. Cardiac Biomarker Sales Others , by Region K Unit (2019-2024)
  • Table 416. Cardiac Biomarker Sales: by Testing Location Type(K Unit)
  • Table 417. Cardiac Biomarker Sales Point of Care Testing , by Region K Unit (2019-2024)
  • Table 418. Cardiac Biomarker Sales Laboratory Testing , by Region K Unit (2019-2024)
  • Table 419. South America Cardiac Biomarker Sales, by Country K Unit (2019-2024)
  • Table 420. South America Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 421. South America Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 422. South America Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 423. South America Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 424. Brazil Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 425. Brazil Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 426. Brazil Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 427. Brazil Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 428. Argentina Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 429. Argentina Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 430. Argentina Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 431. Argentina Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 432. Rest of South America Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 433. Rest of South America Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 434. Rest of South America Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 435. Rest of South America Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 436. Asia Pacific Cardiac Biomarker Sales, by Country K Unit (2019-2024)
  • Table 437. Asia Pacific Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 438. Asia Pacific Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 439. Asia Pacific Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 440. Asia Pacific Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 441. China Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 442. China Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 443. China Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 444. China Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 445. Japan Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 446. Japan Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 447. Japan Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 448. Japan Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 449. India Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 450. India Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 451. India Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 452. India Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 453. South Korea Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 454. South Korea Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 455. South Korea Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 456. South Korea Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 457. Taiwan Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 458. Taiwan Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 459. Taiwan Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 460. Taiwan Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 461. Australia Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 462. Australia Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 463. Australia Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 464. Australia Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 465. Rest of Asia-Pacific Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 466. Rest of Asia-Pacific Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 467. Rest of Asia-Pacific Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 468. Rest of Asia-Pacific Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 469. Europe Cardiac Biomarker Sales, by Country K Unit (2019-2024)
  • Table 470. Europe Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 471. Europe Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 472. Europe Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 473. Europe Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 474. Germany Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 475. Germany Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 476. Germany Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 477. Germany Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 478. France Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 479. France Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 480. France Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 481. France Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 482. Italy Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 483. Italy Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 484. Italy Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 485. Italy Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 486. United Kingdom Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 487. United Kingdom Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 488. United Kingdom Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 489. United Kingdom Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 490. Netherlands Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 491. Netherlands Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 492. Netherlands Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 493. Netherlands Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 494. Rest of Europe Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 495. Rest of Europe Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 496. Rest of Europe Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 497. Rest of Europe Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 498. MEA Cardiac Biomarker Sales, by Country K Unit (2019-2024)
  • Table 499. MEA Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 500. MEA Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 501. MEA Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 502. MEA Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 503. Middle East Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 504. Middle East Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 505. Middle East Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 506. Middle East Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 507. Africa Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 508. Africa Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 509. Africa Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 510. Africa Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 511. North America Cardiac Biomarker Sales, by Country K Unit (2019-2024)
  • Table 512. North America Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 513. North America Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 514. North America Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 515. North America Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 516. United States Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 517. United States Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 518. United States Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 519. United States Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 520. Canada Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 521. Canada Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 522. Canada Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 523. Canada Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 524. Mexico Cardiac Biomarker Sales, by Type K Unit (2019-2024)
  • Table 525. Mexico Cardiac Biomarker Sales, by Application K Unit (2019-2024)
  • Table 526. Mexico Cardiac Biomarker Sales, by End Users K Unit (2019-2024)
  • Table 527. Mexico Cardiac Biomarker Sales, by Testing Location Type K Unit (2019-2024)
  • Table 528. Cardiac Biomarker: by Type(USD/Units)
  • Table 529. Research Programs/Design for This Report
  • Table 530. Key Data Information from Secondary Sources
  • Table 531. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cardiac Biomarker: by Type USD Million (2013-2018)
  • Figure 5. Global Cardiac Biomarker: by Application USD Million (2013-2018)
  • Figure 6. Global Cardiac Biomarker: by End Users USD Million (2013-2018)
  • Figure 7. Global Cardiac Biomarker: by Testing Location Type USD Million (2013-2018)
  • Figure 8. South America Cardiac Biomarker Share (%), by Country
  • Figure 9. Asia Pacific Cardiac Biomarker Share (%), by Country
  • Figure 10. Europe Cardiac Biomarker Share (%), by Country
  • Figure 11. MEA Cardiac Biomarker Share (%), by Country
  • Figure 12. North America Cardiac Biomarker Share (%), by Country
  • Figure 13. Global Cardiac Biomarker: by Type K Unit (2013-2018)
  • Figure 14. Global Cardiac Biomarker: by Application K Unit (2013-2018)
  • Figure 15. Global Cardiac Biomarker: by End Users K Unit (2013-2018)
  • Figure 16. Global Cardiac Biomarker: by Testing Location Type K Unit (2013-2018)
  • Figure 17. South America Cardiac Biomarker Share (%), by Country
  • Figure 18. Asia Pacific Cardiac Biomarker Share (%), by Country
  • Figure 19. Europe Cardiac Biomarker Share (%), by Country
  • Figure 20. MEA Cardiac Biomarker Share (%), by Country
  • Figure 21. North America Cardiac Biomarker Share (%), by Country
  • Figure 22. Global Cardiac Biomarker: by Type USD/Units (2013-2018)
  • Figure 23. Global Cardiac Biomarker share by Players 2018 (%)
  • Figure 24. Global Cardiac Biomarker share by Players (Top 3) 2018(%)
  • Figure 25. Global Cardiac Biomarker share by Players (Top 5) 2018(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Alere Inc. (A Abbott Lab Company) (United States) Revenue, Net Income and Gross profit
  • Figure 28. Alere Inc. (A Abbott Lab Company) (United States) Revenue: by Geography 2018
  • Figure 29. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Roche Holding AG (Switzerland) Revenue: by Geography 2018
  • Figure 31. BG Medicine (Cambodia) Revenue, Net Income and Gross profit
  • Figure 32. BG Medicine (Cambodia) Revenue: by Geography 2018
  • Figure 33. Biomerieux (France) Revenue, Net Income and Gross profit
  • Figure 34. Biomerieux (France) Revenue: by Geography 2018
  • Figure 35. Critical Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 36. Critical Diagnostics (United States) Revenue: by Geography 2018
  • Figure 37. DiaDexus (United States) Revenue, Net Income and Gross profit
  • Figure 38. DiaDexus (United States) Revenue: by Geography 2018
  • Figure 39. Response Biomedical (Canada) Revenue, Net Income and Gross profit
  • Figure 40. Response Biomedical (Canada) Revenue: by Geography 2018
  • Figure 41. Siemens Healthcare (Germany) Revenue, Net Income and Gross profit
  • Figure 42. Siemens Healthcare (Germany) Revenue: by Geography 2018
  • Figure 43. Singulex Inc. (united States) Revenue, Net Income and Gross profit
  • Figure 44. Singulex Inc. (united States) Revenue: by Geography 2018
  • Figure 45. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 46. Thermo Fisher Scientific (United States) Revenue: by Geography 2018
  • Figure 47. Global Cardiac Biomarker: by Type USD Million (2019-2024)
  • Figure 48. Global Cardiac Biomarker: by Application USD Million (2019-2024)
  • Figure 49. Global Cardiac Biomarker: by End Users USD Million (2019-2024)
  • Figure 50. Global Cardiac Biomarker: by Testing Location Type USD Million (2019-2024)
  • Figure 51. South America Cardiac Biomarker Share (%), by Country
  • Figure 52. Asia Pacific Cardiac Biomarker Share (%), by Country
  • Figure 53. Europe Cardiac Biomarker Share (%), by Country
  • Figure 54. MEA Cardiac Biomarker Share (%), by Country
  • Figure 55. North America Cardiac Biomarker Share (%), by Country
  • Figure 56. Global Cardiac Biomarker: by Type K Unit (2019-2024)
  • Figure 57. Global Cardiac Biomarker: by Application K Unit (2019-2024)
  • Figure 58. Global Cardiac Biomarker: by End Users K Unit (2019-2024)
  • Figure 59. Global Cardiac Biomarker: by Testing Location Type K Unit (2019-2024)
  • Figure 60. South America Cardiac Biomarker Share (%), by Country
  • Figure 61. Asia Pacific Cardiac Biomarker Share (%), by Country
  • Figure 62. Europe Cardiac Biomarker Share (%), by Country
  • Figure 63. MEA Cardiac Biomarker Share (%), by Country
  • Figure 64. North America Cardiac Biomarker Share (%), by Country
  • Figure 65. Global Cardiac Biomarker: by Type USD/Units (2019-2024)
List of companies from research coverage that are profiled in the study
  • Alere Inc. (A Abbott Lab Company) (United States)
  • Roche Holding AG (Switzerland)
  • BG Medicine (Cambodia)
  • Biomerieux (France)
  • Critical Diagnostics (United States)
  • DiaDexus (United States)
  • Response Biomedical (Canada)
  • Siemens Healthcare (Germany)
  • Singulex Inc. (united States)
  • Thermo Fisher Scientific (United States)
Select User Access Type

Key Highlights of Report


Sep 2019 221 Pages 97 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global (United States, European Union and China) Cardiac Biomarker Quantitative research analysis
Global (United States, European Union and China) Cardiac Biomarker Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global (United States, European Union and China) Cardiac Biomarker Report?

Have a Query? Click Here

Other Related Reports

Children Audiometers Comprehensive Study by Type (Diagnostic Audiometer, Screening Audiometer), Technology (Stand-alone Audiometer, Hybrid Audiometer, PC-based Audiometer), End-User (Hospitals, Clini...
$ 3450
Drug Delivery Devices Comprehensive Study by Type (Ambulatory infusion pumps, Valves, Needles, Paediatric IV set, Others), Application (Pharmaceutical companies, Hospitals, Clinics, Others), Delivery...
$ 3750
Pressure Infusor Comprehensive Study by Type (Manual Pressure Infusor, Automatic Pressure Infusor), Application (Infusion of IV Solutions, Infusion of Blood, Others), End-users (Hospitals, Clinics, L...
$ 3650
Transvaginal Endoscopy Comprehensive Study by Type (Flexible Endoscope, Rigid Endoscope), Application (Hospitals, Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other...
$ 3500
Ultrasonic Scalpel Comprehensive Study by Type (Silicone Liner, Thermoplastic Elastomer (TPE), Polyurethane Liner), Application (Leg Disabled People, Arm Disabled People), Indication (Lung Biopsy, Gy...
$ 3650
Laboratory Freezers Comprehensive Study by Type (Enzyme Freezers, Laboratory Freezers, Explosion-proof Freezers, Flammable Material Freezers, Plasma Freezers, Ultra-low Temperature Freezers), Freezer...
$ 3750